Self-monitoring of blood glucose (SMBG) is an important adjunct to hemoglobin A1c (HbA1c) testing. This action can distinguish between fasting, preprandial, and postprandial hyperglycemia; detect glycemic excursions; identify and monitor resolution of hypoglycemia; and provide immediate feedback to patients about the effect of food choices, activity, and medication on glycemic control.
Pattern analysis is a systematic approach to identifying glycemic patterns within SMBG data and then taking appropriate action based upon those results. The use of pattern analysis involves: (1) establishing pre- and postprandial glucose targets; (2) obtaining data on glucose levels, carbohydrate intake, medication administration (type, dosages, timing), activity levels and physical/emotional stress; (3) analyzing data to identify patterns of glycemic excursions, assessing any influential factors, and implementing appropriate action(s); and (4) performing ongoing SMBG to assess the impact of any therapeutic changes made.
Computer-based and paper-based data collection and management tools can be developed to perform pattern analysis for identifying patterns in SMBG data. This approach to interpreting SMBG data facilitates rational therapeutic adjustments in response to this information. Pattern analysis of SMBG data can be of equal or greater value than measurement of HbA1c levels.
International Diabetes Federation. Diabetes facts and figures [cited 2008 Nov 1]. Available from: http://www.idf.org.
2.
Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329 (14): 977–86.
3.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352 (9131): 837–53.
4.
StrattonIMAdlerAINeilHAMatthewsDRManleySECullCAHaddenDTurnerRCHolmanRR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ.2000;321 (7258): 405–12.
5.
HolmanRRPaulSKBethelMAMatthewsDRNeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med.2008;359 (15): 1577–89.
6.
GaedePLund-AndersenHParvingHHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med.2008;358 (6)580–91.
7.
GaedePValentineWJPalmerAJTuckerDMLammertMParvingHHPedersenO. Cost-effectiveness of Intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care.2008;31 (8): 1510–5.
8.
RodbardHWBlondeLBraithwaiteSSBrettEMCobinRHHandelsmanYHellmanRJellingerPSJovanovicLGLevyPMechanickJIZangenehF, AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract.2007;13Suppl 1: 1–68.
9.
El-OstaABrasacchioDYaoDPocaiAJonesPLRoederRGCooperMEBrownleeM. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med.2008;205 (10): 2409–17.
10.
Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes.1995;44 (8): 968–83.
11.
International Diabetes Federation Guideline Development Committee. Guideline for management of postmeal glucose. Brussels: International Diabetes Federation; 2007.
12.
SorkinJDMullerDCFlegJLAndresR. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care.2005;28 (11): 2626–32.
13.
LevitanEBSongYFordESLiuS. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med.2004;164 (19): 2147–55.
14.
CavalotFPetrelliATraversaMBonomoKFioraEContiMAnfossiGCostaGTrovatiM. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab.2006;91 (3): 813–9.
15.
CerielloAQuagliaroLPiconiLAssaloniRDaRRMaierAEspositoKGiuglianoD. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes.2004;53 (3): 701–10.
16.
HanefeldMKoehlerCSchaperFFueckerKHenkelETemelkova-KurktschievT. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis.1999;144 (1): 229–235.
17.
WilliamsSBGoldfineABTimimiFKTingHHRoddyMASimonsonDCCraegerMA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation.1998;97 (17): 1695–1701.
18.
KawanoHMotoyamaTHirashimaOHiraiNMiyaoYSakamotoTKugiyamaKOgawaHYasueH. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol.1999;34 (1): 146–54.
19.
HanefeldMCagatayMPetrowitschTNeuserDPetzinnaDRuppM. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J.2004;25 (1): 10–6.
20.
EspositoKGiuglianoDNappoFMarfellaR, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation.2004;110 (2): 214–9.
21.
CerielloAFalletiEMotzETabogaCTonuttiLEzsolZGonanoFBartoliE. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res.1998;30 (3): 146–9.
22.
CominaciniLFrattaPAGarbinUCampagnolaMDavoliARigoniAZentiMGPastorinoAMLo CascioV. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia.1997;40 (5): 584–9.
23.
NappoFEspositoKCioffiMGiuglianoGMolinariAMPaolissoGMarfellaRGiuglianoD. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol.2002;39 (7): 1145–50.
24.
EspositoKNappoFMarfellaRGiuglianoGGiuglianoFCiotolaMQuagliaroLCerielloAGiuglianoD. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation.2002;106 (16): 2067–72.
25.
MarfellaRQuagliaroLNappoFCerielloAGiuglianoD. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest.2001;108 (4): 635–6.
26.
GerichJE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med.2003;163 (11): 1306–16.
27.
KhatriJJJohnsonCMagidRLessnerSMLaudeKMDikalovSIHarrisonDGSungHJRongYGalisZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation.2004;109 (4): 520–5.
28.
von HarsdorfRLiPFDietzR. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation.1999;99 (22): 2934–41.
29.
BrownleeM. Biochemistry and molecular cell biology of diabetic complications. Nature.2001;414 (6865): 813–20.
30.
MonnierLMasEGinetCMichelFVillonLCristolJPColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA.2006;295 (14): 1681–7.
31.
SchiekoferSAndrassyMChenJRudofskyGSchneiderJWendtTStefanNHumpertPFritscheAStumvollMSchleicherEHäringHUNawrothPPBierhausA. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes.2003;52 (3): 621–33.
32.
AkbarDH. Sub-optimal postprandial blood glucose level in diabetics attending the outpatient clinic of a University Hospital. Saudi Med J.2003;24 (10): 1109–12.
33.
ErlingerTPBrancatiFL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care.2001;24 (10): 1734–8.
34.
MaiaFFAraujoLR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract.2007;75 (1): 30–4.
35.
BonoraECorraoGBagnardiVCerielloAComaschiMMontanariPMeigsJB. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia.2006;49 (5): 846–54.
36.
EspositoKCiotolaMCarleoDSchisanoBSardelliLDi TommasoDMissoLSaccomannoFCerielloAGiuglianoD. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab.2008;93 (4): 1345–50.
37.
DaileyG. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements. Mayo Clin Proc.2007;82 (2): 229–35.
38.
AustinMMHaasLJohnsonTParkinCGParkinCLSpollettGVolponeMT. Self-monitoring of blood glucose: benefits and utilization. Diabetes Educ.2006;32 (6): 835–6, 884–7.
39.
American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care.2008;31Suppl 1: S12–S54.
40.
American Association of Clinical Endrocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management–2000 update. Endocr Pract.2000;6 (1): 43–84.
41.
AbrairaCColwellJANuttallFQSawinCTNagelNJComstockJPEmanueleNVLevinSRHendersonWLeeHS. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care.1995;18 (8): 1113–23.
42.
JellingerPSDavidsonJABlondeLGrunbergerGHellmanRLevyP. Road map to achieve glycemic goals. Jacksonville (FL): American Association of Clinical Endocrinologists; 2008.
43.
LingvayIKaloyanovaPFAdams-HuetBSalinasKRaskinP. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med.2007;55 (2): 62–8.
44.
RiddleMCRosenstockJGerichJ. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.200326 (11): 3080–6.
45.
GarberAJWahlenJWahlTBresslerPBracerasRAllenEJainR. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab.2006;8 (1): 58–66.
46.
GoldbergJDFranklinBLasserDJornsayDLHausknechtRUGinsberg-FellnerFBerkowitzRL. Gestational diabetes: impact of home glucose monitoring on neonatal birth weight. Am J Obstet Gynecol.1986;154 (3): 546–50.
47.
JensenDMDammPMoelsted-PedersenLOvesenPWestergaardJGMoellerMBeck-NielsenH. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care.2004;27 (12): 2819–23.
48.
JovanovicLG. Using meal-based self-monitoring of blood glucose as a tool to improve outcomes in pregnancy complicated by diabetes. Endocr Pract.2008;14 (2): 239–47.
49.
YlinenKAulaPStenmanUHKesaniemi-KuokkanenTTeramoK. Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. Br Med J (Clin Res Ed).1984;289 (6441): 345–6.
50.
De VecianaMMajorCMorganMAsratTTooheyJLienJEvansAT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med.1995;333 (19): 1237–41.
51.
IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 2006. Available from: http://www.idf.org.
52.
KlonoffDC. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes—when this practice is not applied properly. J Diabetes Sci Technol.2008;2 (3): 342–8.
53.
ParkinCGPriceD. Randomized studies are needed to assess the true role of self-monitoring of blood gluocse in noninsulin-treated type 2 diabetes. J Diabetes Sci Technol.2007: 1 (4): 595–602.
54.
BarnettAHKrentzAJStrojekKSieradzkiJAziziFEmbongMImamogluSPerusicováJUlicianskyVWinklerG. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen: A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab.2008;10 (12): 1239–47.
55.
FarmerAWadeAGoyderEYudkinPFrenchDCravenAHolmanRKinmonthALNeilA. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ.2007;335 (7611): 132.
56.
DavidsonMBCastellanosMKainDDuranP. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med.2005;118 (4): 422–5.
57.
JansenJP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin.2006;22 (4): 671–81.
58.
GuerciBDrouinPGrangeVBougneresPFontainePKerlanVPassaPThivoletChVialettesBCharbonnelB, ASIA Group. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab.2003;29 (6): 587–94.
59.
MorelandECVolkeningLKLawlorMTChalmersKAAndersonBJLaffelLM. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Arch Intern Med.2006;166 (6): 689–95.
60.
SchwedesUSieboldsMMertesG, SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care.2002;25 (11): 1928–32.
61.
MartinSSchneiderBHeinemannLLodwigVKurthHJKolbHScherbaumWA. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia.2006;49 (2): 271–8.
62.
MurataGHShahJHHoffmanRMWendelCSAdamKDSolvasPABokhariSUDuckworthWC, Diabetes Outcomes in Veterans Study (DOVES). Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care.2003;26 (6): 1759–63.
63.
SarolJNJr.NicodemusNAJr.TanKMGravaMB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004). Curr Med Res Opin.2005;21 (2): 173–84.
64.
WelschenLMBloemendalENijpelsGDekkerJMHeineRJStalmanWABouterLM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care.2005;28 (6): 1510–7.
65.
CosterSGullifordMCSeedPTPowrieJKSwaminathanR. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med.2000;17 (11): 755–61.
66.
SimonJGrayAClarkePWadeANeilAFarmerA, Diabetes Glycaemic Education and Monitoring Trial Group. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ.2008;336 (7654): 1177–80.
67.
O'KaneMJBuntingBCopelandMCoatesVE, ESMON study group. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ.2008;336 (7654): 1174–7.
68.
MilesPEverettJMurphyJKerrD. Comparison of blood or urine testing by patients with newly diagnosed non-insulin dependent diabetes: patient survey after randomised crossover trial. BMJ.1997;315 (7104): 348–9.
69.
ParkinCGHirschIB. Self-monitoring of blood glucose cannot compensate for ineffective diabetes management. Am J Med.2005;118 (12): 1448–9.
70.
McIntoshAHutchinsonAHomePBrownFBruceADamerellADavisRFieldRFrostGMarshallSRoddickJTesfayeSWithersHSucklingRSmithSGriffinSKaltenthalerEPetersJFederG. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield; 2001.
71.
MonnierLLapinskiHColetteC. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care.2003;26 (3): 881–5.
72.
ParkinCBrooksN. Is postprandial glucose control important? Is it practical in primary care settings?. Clin Diabetes.2002;20: 71–6.
73.
PearsonJBergenstalR. Fine-tuning control: pattern management versus supplementation: View 1: Pattern management: an essential component of effective insulin management. Diabetes Spectrum.2001;14: 75–8.
74.
ChoJHChangSAKwonHSChoiYHKoSHMoonSDYooSJSongKHSonHSKimHSLeeWCChaBYSonHYYoonKH. Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care.2006;29 (12): 2625–31. t.
75.
CoxDJGonder-FrederickLRitterbandLClarkeWKovatchevBP. Prediction of severe hypoglycemia. Diabetes Care.2007;30 (6): 1370–3.
76.
KovatchevBPCoxDJGonder-FrederickLAYoung-HymanDSchlundtDClarkeW. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care.1998;21 (11): 1870–5.
77.
KovatchevBPCoxDJGonder-FrederickLAClarkeW. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care.1997;20 (11): 1655–8.
78.
HirschIB. Blood glucose monitoring technology: translating data into practice. Endocr Pract.2004;10 (1): 67–76.
79.
ChildsBLaanR. Development of a novel blood glucose analysis system for episodic bG monitoring in persons with type 2 diabetes. Diabetes.2007;56Suppl 1: 427.
80.
PolonskyWJelsovskyAPanzeraSParkinCWagnerR. Primary care physicians identify and act upon glycemic abnormalities found in structured, episodic blood glucose monitoring data from non-insulin treated type 2 diabetes. Diabetes Technol Ther.2009;(In press).
81.
ClinicalTrials.gov [homepage on the Internet]. Episodic intensive blood glucose monitoring in non-insulin treated type 2 diabetes. Bethesda (MD): National Institutes of HealthNational Institutes of Health; 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00674986.
